Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies - Report - MDSpire
Advertisement
Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies
Clinical Report: Comparative Analysis of Axial Psoriatic Arthritis and Axial Spondyloarthritis
Overview
This systematic review and meta-analysis compares clinical features of axial psoriatic arthritis (ax-PsA) and axial spondyloarthritis (ax-SpA). Key findings indicate significant differences in HLA-B27 positivity, while disease activity and functional outcomes are similar between the two conditions.
Background
Axial psoriatic arthritis (ax-PsA) is a subset of psoriatic arthritis (PsA) characterized by axial involvement, which presents similarly to axial spondyloarthritis (ax-SpA). The classification of ax-PsA remains uncertain, leading to ongoing debate regarding its distinction from ax-SpA.
Data Highlights
Measure
ax-PsA
ax-SpA
HLA-B27 Positivity
40%
90%
BASDAI
No significant difference
No significant difference
BASFI
−0.35 (mean difference)
No significant difference
CRP Levels
No significant difference
No significant difference
Key Findings
ax-PsA shows significantly lower HLA-B27 positivity compared to ax-SpA (risk ratio, 0.37; p < 0.001).
No significant differences in disease activity scores (BASDAI, ASDAS-CRP) between ax-PsA and ax-SpA.
Subgroup analyses indicate ax-PsA has modestly better BASFI scores than ax-SpA (mean difference, 0.35; p = 0.022).
Both conditions exhibit similar functional outcomes.
Clinical differentiation should include HLA-B27 testing and imaging.
Clinical Implications
The findings support the need for HLA-B27 testing in clinical practice to differentiate between ax-PsA and ax-SpA. Understanding the distinct characteristics of ax-PsA may guide more tailored therapeutic approaches.
Conclusion
The study highlights the distinct nature of ax-PsA compared to ax-SpA, particularly regarding HLA-B27 positivity, while also indicating similarities in disease activity and functional outcomes.
